A Trail of Sperstent® Used for Residual Lesions of Femoropopliteal Arteries

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 240 participants.

Also called NCT06539689

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 240 participants (planned count) (from the registry)
Sponsor
FrontAce Scientific Co., Ltd (from the registry)
Registry
  • NCT NCT06539689
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06539689. Randomized; no masking; primary purpose treatment. Start 2024-06-04 (actual); primary completion 2026-12-04 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Trail of Sperstent® Used for Residual Lesions of Femoropopliteal Arteries
Acronym
SURF
Condition
Peripheral Arterial Disease
Condition
Stenosis
Condition
Dissection
Intervention (Device)
Sperstent® peripheral spot stent system
Intervention (Device)
Everflex® self-expanding peripheral stent system
Lead sponsor
FrontAce Scientific Co., Ltd (class: industry)

Record details

Record id
cardio:ct-nct06539689
Content hash
988fac28e480cfb5d5542a9bbe346afda77b01776eca1f79facca7664adf8889